Regeneron Pharmaceuticals' Change in Receivables fell 79.35% to $80.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.5 million, marking a year-over-year decrease of 183.16%. This contributed to the annual value of $554.0 million for FY2024, which is 63.52% up from last year.
As of FY2024, Regeneron Pharmaceuticals' Change in Receivables stood at $554.0 million, which was up 63.52% from $338.8 million recorded in FY2023.
In the past 5 years, Regeneron Pharmaceuticals' Change in Receivables registered a high of $1.9 billion during FY2021, and its lowest value of -$707.8 million during FY2022.
Over the past 3 years, Regeneron Pharmaceuticals' median Change in Receivables value was $338.8 million (recorded in 2023), while the average stood at $61.7 million.
Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 158.95% in 2020, then tumbled by 136.72% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Change in Receivables (Yearly) stood at $1.4 billion in 2020, then soared by 42.13% to $1.9 billion in 2021, then plummeted by 136.72% to -$707.8 million in 2022, then soared by 147.87% to $338.8 million in 2023, then surged by 63.52% to $554.0 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value